Scherle Peggy

Scherle Peggy is listed in filings as Chief Scientific Officer at Prelude Therapeutics Incorporated. This profile follows SEC Form 4 activity through Feb 5, 2026, including 2 public disclosures. Recent filings connect the profile to Prelude Therapeutics Incorporated (PRLD). The current snapshot covers public activity from Feb 5, 2025 to Feb 5, 2026. Reported amounts are shown as $529.0K to $194.3K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.